Dr. Sledge on Using Tumor Heterogeneity to Guide Treatment in Breast Cancer

George W. Sledge, Jr., MD
Published: Saturday, Feb 28, 2015



George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine, explains how tumor heterogeneity impacts patient care and research.

Sledge says within a primary breast cancer, the tumor can express different sensitivities. This brings up a challenging question for physicians about which sensitivity to target. Guidelines help physicians define the tumor type, Sledge says.

In the metastatic setting, significant differences can exist between the primary tumor and the first site of metastasis. This is due in part to the cancer changing in an attempt to resist therapy. Sledge says it is important to rebiopsy patients at the time of metastatic disease in order to better treat the cancer.

<<< View more from the 32nd Annual Miami Breast Cancer Conference



George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine, explains how tumor heterogeneity impacts patient care and research.

Sledge says within a primary breast cancer, the tumor can express different sensitivities. This brings up a challenging question for physicians about which sensitivity to target. Guidelines help physicians define the tumor type, Sledge says.

In the metastatic setting, significant differences can exist between the primary tumor and the first site of metastasis. This is due in part to the cancer changing in an attempt to resist therapy. Sledge says it is important to rebiopsy patients at the time of metastatic disease in order to better treat the cancer.

<<< View more from the 32nd Annual Miami Breast Cancer Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x